4 edition of Monoclonal antibody-based therapy of cancer found in the catalog.
Includes bibliographical references and index.
|Statement||edited by Michael L. Grossbard.|
|Series||Basic and clinical oncology ;, 15|
|Contributions||Grossbard, Michael L., 1960-|
|LC Classifications||RC271.M65 M658 1998|
|The Physical Object|
|Pagination||xii, 451 p. :|
|Number of Pages||451|
|LC Control Number||98029118|
Background. Despite major advances in our understanding of cancer biology and technological advances in cancer diagnosis and therapy over past three decades, cancer is a global health problem and a major cause of death worldwide. 1,2 In the UK, there were over new cancer cases and cancer was responsible for deaths in Worldwide, there were an Cited by: Read here ?book= Read Cancer Therapy: Monoclonal Antibodies Lymphokines New Developments in Surgical Oncology.
With the increased application of antibody-based therapies in MM, clinicians will now have to manage antibody-related adverse events, such as infusion-related reactions (IRRs). Furthermore, because many laboratory tests are based on specific antibody-antigen interactions, interference of therapeutic antibodies is increasingly being by: With their role in connecting disease-associated antigens to the cellular immune response, antibodies hold considerable promise as therapeutic agents. This chapter discusses three classes of therapeutic antibodies that have been developed for use in ovarian cancer therapy. The first includes antibodies selected against tumor-associated antigens such as MUC16/CA, mesothelin, epithelial cell Author: Yousef Alharbi.
Monoclonal antibodies (mAb or moAb) are antibodies that are made by identical immune cells that are all clones of a unique parent cell. Monoclonal antibodies can have monovalent affinity, in that they bind to the same epitope (the part of an antigen that is recognized by the antibody). In contrast, polyclonal antibodies bind to multiple epitopes and are usually made by several different plasma. First attempts to use exogenous mRNA for protein expression in vivo were made more than 25 years ago. However, widespread appreciation of in vitro transcribed mRNA as a powerful technology for supplying therapeutic proteins to the body has evolved only during the past few years. Various approaches to turning mRNA into a potent therapeutic have been by: 1.
Sketches for sermons
Lettering for children.
St. Columba Derry and Raphoe celebrations 1963.
Modern electric and gas refrigeration
Aciklamali makina meslek resmi
Description of Buxton, Chatsworth, and Castleton
chemistry of nucleic acids.
Tremeears annotated criminal code
From Medicine to Mysticism
Effect of nitrogen starvation and the role of carboxysomes in four species of Oscillatoria (Cyanophyceae).
Overcrowding in the household
If you're considering monoclonal antibody therapy as part of your cancer treatment, learn about these drugs and carefully weigh the benefits against the potential side effects. By Mayo Clinic Staff Monoclonal antibody drugs are cancer treatments that enlist natural immune system functions to fight cancer.
In a proof-of-concept study of patients (n = ) with HER2+ metastatic breast cancer who have progressed after prior treatment with chemotherapy and HER2-directed therapy (trastuzumab, lapatinib), the objective response rate (ORR) was 26% by independent review and the median progression-free survival (PFS) was months (Burris et al., Cited by: NOTE: Some m onoclonal antibodies used to treat cancer are referred to as targeted therapy because they have a specific target on a cancer cell that they aim to find, attach to, and attack.
But other monoclonal antibodies act like immunotherapy because they make the immune system respond better to allow the body to find and attack cancer cells. Presents comprehensive discussions of applications of monoclonal antibody-based agents as front-line and adjuvant treatments in cancer.
This book highlights the impact of these therapies in areas such as improved response rates and safety profiles while providing an understanding of their present limitations. - Buy Monoclonal Antibody-Based Therapy of Cancer: 15 (Basic and Clinical Oncology) book online at best prices in India on Read Monoclonal Antibody-Based Therapy of Cancer: 15 (Basic and Clinical Oncology) book reviews & author details Author: Michael L.
Grossbard. Monoclonal antibody-based targeted therapy in breast cancer: current status and future directions. Bernard-Marty C(1), Lebrun F, Awada A, Piccart MJ. Author information: (1)Jules Bordet Institute, Brussels, by: 83 rows Monoclonal antibody therapy is a form of immunotherapy that uses monoclonal antibodies.
For 20 years, monoclonal antibodies (mAbs) have been a standard component of cancer therapy, yet there is still much room for improvement.
Efforts continue to build better cancer therapeutics based on mAbs. Anti-cancer mAbs function via a variety of mechanisms Cited by: Antibody-based therapeutics have emerged as important components of therapies for an increasing number of human malignancies ().Unconjugated mAbs directed against the B Cited by: Recent studies have suggested that pediatric-intensive chemotherapy regimens can improve outcomes in adults with acute lymphoblastic leukemia (ALL) up to the age of Above this age, toxicities increase.
Monoclonal antibody-based therapies bring the promise of increased response rates without excessive toxicity. The addition of rituximab to combination chemotherapy has shown encouraging Cited by: Antibody-based therapy for cancer has become estab-lished over the past 15 years and is now one of the most successful and important strategies for treating patients with haematological malignancies and solid tumours.
The fundamental basis of antibody-based therapy of tumours dates back to the original observations of antigen expres. Monoclonal antibodies are biological drugs used to treat cancers, certain types of arthritis, lupus, MS, and IBD.
Side effects are itching, rash, chills, cough and constipation, and may include hepatitis, cancer and congestive heart failure. Antibody-based therapy for cancer has become established over the past 15 years and is now one of the most successful and important strategies for treating patients with haematological Cited by: B.
Ayach, J.C. Plana, in Anti-Cancer Treatments and Cardiotoxicity, Monoclonal Antibodies (Bevacizumab) Bevacizumab, a novel antiangiogenic agents and recombinant humanized monoclonal antibody agent against vascular endothelial growth factor (VEGF) targeting new vessel formation, is widely used in cancer treatment and has shown a significant survival benefit in colorectal, renal, and.
Kramer K, Gerald W, Kushner BH, et al.: Disialoganglioside GD2 loss following monoclonal antibody therapy is rare in Can Res–Antigen loss is another reason for resistance to antibody-based therapy. In a large series of patients with consecutive studies of G D2 expression before and after anti-G D2 antibody treatment, G D2 loss was by: Monoclonal antibody-based therapy of cancer.
New York: Dekker, © (DLC) (OCoLC) Material Type: Document, Internet resource: Document Type: Internet Resource, Computer File: All Authors / Contributors: Michael L Grossbard. Monoclonal Antibody-Based Targeted Therapy in Breast Cancer Article Literature Review in Drugs 66(12) February with 58 Reads How we measure 'reads'.
Key Words immunoconjugate, immunotoxin, radioimmunotherapy, antibody-dependent cellular cytotoxicity s Abstract Monoclonal antibody therapy has emerged as. Monoclonal antibody therapy is the use of monoclonal antibodies (or mAb) to specifically target cells.
The main objective is stimulating the patient's immune system to attack the malignant tumor. In light of recent clinical breakthroughs in the field, this lucid book presents up-to-date and comprehensive discussions of current and potential applications of monoclonal antibody-based agents as frontline and adjuvant treatments in cancer-highlighting the impact of these therapies in areas such as improved response rates and safety profiles while providing an informed understanding of.
Treatment in patients with colorectal cancer at the advanced stage is challenging. Find out if antibody-based therapies are the key to brighter days ahead.Safety, pharmakokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer.
J Clin Oncol 22(15), –, PubMed CrossRef Google ScholarAuthor: Axel Bex, Simon Horenblas, Gijsbert C. de Gast.Monoclonal antibodies are effective treatments for many malignant diseases.
However, the ability of antibodies to initiate tumour-antigen-specific immune responses has received less attention than have other mechanisms of antibody action. We describe the rationale and evidence for the development of antibodies that can stimulate host tumour-antigen-specific immune by: